Furthermore, combination of ERK5 and CDK5 inhibition with XMD8-92 and Seliciclib, synergize in suppressing FAK and are expected to prevent feedback signaling leading to drug resistance, providing an additional treatment option for lung cancer patients with KRAS mutations. This evidence concerns the gene KRAS and lung carcinoma.